Basic Information

Gene symbol CD33 Synonyms CD33rSiglec, SIGLEC-3, SIGLEC3, p67 Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas
Description CD33 molecule

GTO ID GTC0174
Trial ID NCT01864902
Disease Myeloid Leukemia
Altered gene CD33
Therapeutic/Target gene Target gene
TherapyCAR-T cell
Treatment CD33 CAR-T cells
Generation2nd
PhasePhase1|Phase2
Recruitment statusUnknown
TitleTreatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33
Year2013
CountryChina
Company sponsorChinese PLA General Hospital
Other ID(s)CHN-PLAGH-BT-006
Vector information
Vectorlentivirus
ConstructCAR-33-4-1BBζ-GFP
Transgene/Inserted geneanti-CD33 scFv; human CD8α hinge and transmembrane domains; human 4-1BB and CD3ζ signaling domains
Vector production methodThe cells were cultured in GT-T551 medium and activated by the addition of antihuman CD3 monoclonal antibody (Takara, Japan), recombinant human IL-2 (rhIL-2; Peprotech, Rocky Hill, NJ), and recombinant human interferon (IFN)-γ (Peprotech). The cells were transferred from the coated flasks to fresh flasks after 4 days. Fresh medium and 1,000 U/ml rhIL-2 were added every 3 days. The composition and purity were assessed by fluorescent-activated cell sorting on days 10-11. The cells were then harvested and termed as CART-33 cells.
Additional featureGFP

Clinical Result

Cohort 1
Administration route intravenous infusion
Dosage 1.12E9 cells
Donor type Autologous
Pts 1
Age Child, Adult, Older_Adult
Lymph depletion No
Outcome 1/1(CR)
Adverse reactions 1/1(chills; high fever)
References PMID: 25174587

Relationship Graph

Overview of Knowledge Graph